Network Analysis of Associations Between Serum Interferon-alpha Activity, Autoantibodies, and Clinical Features in Systemic Lupus Erythematosus

University of Chicago, Chicago, IL, USA.
Arthritis & Rheumatology (Impact Factor: 7.87). 04/2011; 63(4):1044-53. DOI: 10.1002/art.30187
Source: PubMed

ABSTRACT Interferon-α (IFNα) is a primary pathogenic factor in systemic lupus erythematosus (SLE), and high IFNα levels may be associated with particular clinical manifestations. The prevalence of individual clinical and serologic features differs significantly by ancestry. This study was undertaken to detect associations between clinical and serologic disease manifestations and serum IFNα activity in a large diverse SLE cohort, using multivariate and network analyses.
We studied 1,089 SLE patients (387 African American, 186 Hispanic American, and 516 European American patients). The presence or absence of individual American College of Rheumatology (ACR) clinical criteria for SLE, autoantibodies, and serum IFNα activity data were analyzed in univariate and multivariate models. Iterative multivariate logistic regression was performed in each ancestral background group separately to establish the network of associations between variables that were independently significant following Bonferroni correction.
In all ancestral backgrounds, high IFNα activity was associated with anti-Ro and anti-double-stranded DNA antibodies (P = 4.6 × 10(-18) and P = 2.9 × 10(-16) , respectively). Younger age, non-European ancestry, and anti-RNP were also independently associated with increased serum IFNα activity (P ≤ 6.7 × 10(-4) ). We found 14 unique associations between variables in network analysis, and only 7 of these associations were shared among >1 ancestral background. Associations between clinical criteria were different for different ancestral backgrounds, while autoantibody-IFNα relationships were similar across backgrounds. IFNα activity and autoantibodies were not associated with ACR clinical features in multivariate models.
Our findings indicate that serum IFNα activity is strongly and consistently associated with autoantibodies, and not independently associated with clinical features in SLE. IFNα may be more relevant to humoral tolerance and initial pathogenesis than later clinical disease manifestations.

Download full-text


Available from: Jennifer A Kelly, Dec 12, 2014
  • Source
    • "Many lines of evidence underscore the importance of cytokines in SLE susceptibility. Circulating interferon alpha (IFN-í µí»¼) levels are high in many SLE patients [2] [3]. One of the most direct lines of evidence suggesting that high IFN-í µí»¼ is a primary pathogenic factor is that some individuals treated with recombinant interferon alpha (IFN-í µí»¼) for viral hepatitis develop de novo SLE, which typically resolves when IFN-í µí»¼ treatment is discontinued [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic lupus erythematosus (SLE) patients frequently have high circulating tumor necrosis factor alpha (TNF- α ) levels. We explored circulating TNF- α levels in SLE families to determine whether high levels of TNF- α were clustered in a heritable pattern. We measured TNF- α in 242 SLE patients, 361 unaffected family members, 23 unaffected spouses of SLE patients, and 62 unrelated healthy controls. Familial correlations and relative recurrence risk rates for the high TNF- α trait were assessed. SLE-affected individuals had the highest TNF- α levels, and TNF- α was significantly higher in unaffected first degree relatives than healthy unrelated subjects (P = 0.0025). No Mendelian patterns were observed, but 28.4% of unaffected first degree relatives of SLE patients had high TNF- α levels, resulting in a first degree relative recurrence risk of 4.48 (P = 2.9 × 10(-5)). Interestingly, the median TNF- α value in spouses was similar to that of the first degree relatives. Concordance of the TNF- α trait (high versus low) in SLE patients and their spouses was strikingly high at 78.2%. These data support a role for TNF- α in SLE pathogenesis, and TNF- α levels may relate with heritable factors. The high degree of concordance in SLE patients and their spouses suggests that environmental factors may also play a role in the observed familial aggregation.
    Clinical and Developmental Immunology 09/2013; 2013:267430. DOI:10.1155/2013/267430 · 2.93 Impact Factor
  • Source
    • "For example, specific autoantibodies are formed in some patients and not others, and these autoantibody specificities have been associated with clinical features of the disease [2] [3]. In addition, approximately half of adult patients with SLE demonstrate overactivity of the interferon alpha (IFN-α) pathway in their peripheral blood [2] [4]. Interestingly, high IFN-α and SLE-associated autoantibodies are heritable as traits in SLE families and can be found in family members who are not affected by SLE [5] [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disorder characterized by differences in autoantibody profiles, serum cytokines, and clinical manifestations. We have previously conducted a case-case genome-wide association study (GWAS) of SLE patients to detect associations with autoantibody profile and serum interferon alpha (IFN-α). In this study, we used public gene expression data sets to rationally select additional single nucleotide polymorphisms (SNPs) for validation. The top 200 GWAS SNPs were searched in a database which compares genome-wide expression data to genome-wide SNP genotype data in HapMap cell lines. SNPs were chosen for validation if they were associated with differential expression of 15 or more genes at a significance of P < 9 × 10(-5). This resulted in 11 SNPs which were genotyped in 453 SLE patients and 418 matched controls. Three SNPs were associated with SLE-associated autoantibodies, and one of these SNPs was also associated with serum IFN-α (P < 4.5 × 10(-3) for all). One additional SNP was associated exclusively with serum IFN-α. Case-control analysis was insensitive to these molecular subphenotype associations. This study illustrates the use of gene expression data to rationally select candidate loci in autoimmune disease, and the utility of stratification by molecular phenotypes in the discovery of additional genetic associations in SLE.
    Clinical and Developmental Immunology 07/2012; 2012:682018. DOI:10.1155/2012/682018 · 2.93 Impact Factor
  • Source
    • "In mouse models, OPN is essential for the production of interferon-alpha (IFN-α) [16]. IFN-α levels are elevated in many SLE patients [17] [18], and high IFN-α is a heritable risk factor for SLE [19]. In previous work, we have shown that the SLE risk-associated allele of OPN rs9138C was associated with higher levels of serum OPN and IFN-α in young women and men with SLE [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Variants of the osteopontin (OPN) gene have been associated with systemic lupus erythematosus (SLE) susceptibility and cytokine profiles in SLE patients. It is not known whether these alleles are associated with specific clinical phenotypes in SLE. We studied 252 well-characterized SLE patients from a multiethnic cohort, genotyping the rs11730582, rs28357094, rs6532040, and rs9138 SNPs in the OPN gene. Ancestry informative markers were used to control for genetic ancestry. The SLE-risk allele rs9138C in the 3' UTR region was associated with photosensitivity in lupus patients across all ancestral backgrounds (meta-analysis OR = 3.2, 95% CI = 1.6-6.5, P = 1.0 × 10⁻³). Additionally, the promoter variant rs11730582C demonstrated suggestive evidence for association with two hematologic traits: thrombocytopenia (OR = 2.1, P = 0.023) and hemolytic anemia (OR = 2.6, P = 0.036). These clinical associations with SNPs in the promoter and 3' UTR regions align with previously reported SLE-susceptibility SNPs in OPN and suggest potential roles for these variants in antibody-mediated cytopenias and skin inflammation in SLE.
    BioMed Research International 10/2011; 2011:802581. DOI:10.1155/2011/802581 · 2.71 Impact Factor
Show more